RxDoctor Payments Data

Nay Aung, MD

Diabetology · Utica, NYNPI 1972911352

Payments from drug & device makers

$12,133in general payments, 2019–2025

Across 40 payments — averaging $303.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$12K
  • Abbott$84
  • AstraZeneca$67
  • Lilly USA, LLC$51
  • AbbVie$45
  • Johnson & Johnson$35
  • plus $194 from 8 others

What the payments were for

  • Consulting fees$9,88181%
  • Travel & lodging$1,0308%
  • Food & beverage$1,1279%
  • Education$951%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few diabetology providers in New Yorkto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$29,939
Medicare patients
177
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide532$530,832
JardianceEmpagliflozin355$233,812
Synjardy XrEmpagliflozin/Metformin Hcl118$76,828
TrulicityDulaglutide66$64,008
MounjaroTirzepatide46$45,616
JanuviaSitagliptin Phosphate55$36,833
TradjentaLinagliptin38$22,850
Lantus SolostarInsulin Glargine,hum.Rec.Anlog157$17,787
SynjardyEmpagliflozin/Metformin Hcl21$17,754
Fiasp FlextouchInsulin Aspart (Niacinamide)26$16,482
FarxigaDapagliflozin Propanediol17$15,916
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog52$14,327
RybelsusSemaglutide12$14,300
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$11,267
InvokanaCanagliflozin14$7,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$11,657$545,132544 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy$33$351,244532 claims
Lilly USA, LLCTrulicity, Mounjaro$51$109,624112 claims
AstraZenecaFarxiga$67$15,91617 claims
Johnson & JohnsonInvokana$35$7,66014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few diabetology providers in New Yorkon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →